FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.
Winrevair, PAH treatment for adults, likely available soon in US
Apr 10, 2024 · Winrevair (sotatercept-csrk), the under-the-skin injectable treatment recently approved in the U.S. for adults with pulmonary arterial hypertension (PAH), is expected to be available for dispensing at CVS and Accredo pharmacies by late April, Merck reports.
Winrevair: FDA approves new drug that may help stop PAH | CNN
Mar 26, 2024 · Winrevair was approved by the FDA on Tuesday to help treat pulmonary arterial hypertension. Winrevair is a biologic drug designed to grab onto and trap proteins called activins that are...
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and...
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR …
Nov 25, 2024 · WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality. Study to be stopped early and participants will be offered the opportunity to receive WINREVAIR.
FDA approves sotatercept, now Winrevair, to treat PAH in adults
Mar 27, 2024 · The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to treat adults with pulmonary arterial hypertension (PAH).
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion ...
3 days ago · Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH ...
Winrevair 'overwhelming' at treating advanced PAH in Phase 3 trial
Nov 27, 2024 · Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary arterial hypertension (PAH) at a high risk of dying enrolled in a Phase 3 clinical trial.
Merck Drug for Heart and Lung Disorder Wins a First-in ... - MedCity News
Mar 26, 2024 · Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion...
FDA Approves Winrevair for Pulmonary Arterial Hypertension in …
THURSDAY, March 28, 2024 -- The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults. The FDA previously granted Winrevair a breakthrough therapy designation.